Feature | February 10, 2010| Habib Samady, M.D.

FFR Draws Increased Interest in the Wake of FAME Study

These results are turning heads and changing minds in the cardiology world.

St. Jude Medicals PressureWire Aeris provides wireless integration of FFR data directly into the GE Healthcare Mac-Lab hemodynamic recording system.

Editor’s note: Dr. Samady is an associate professor of medicine, division of cardiology,
Emory University School of Medicine, Atlanta. He wrote the following commentary on his experience with FFR and its impact on patient care.

Since the results of the FAME study were published in January 2009, cardiologists have begun warming up to fractional flow reserve (FFR) as a diagnostic tool. The data presented from FAME (FFR vs. Angiography for Multivessel Evaluation) , compared the outcomes of 1,005 patients 12 months after percutaneous intervention for multivessel coronary artery disease based on either FFR measurement or angiography alone.

The FAME data demonstrates improved clinical and cost-effectiveness outcomes for the patient group that underwent FFR. The FFR method correlated with a 30 percent reduction in major adverse cardiac events after one year — and it lowered the per-patient cost of PCI by an average of $675 without lengthening the procedure.

These results are turning heads and changing minds in the cardiology world. Many doctors who once shied away from FFR, including some fellows and colleagues at Emory, are now starting to ask questions about the technique. As this increased interest leads to increased use, more cardiologists are recognizing the value of FFR as a tool for evaluating the functional severity of coronary stenosis prior to PCI.

FFR involves inserting a coronary pressure guidewire into an artery to measure blood flow, which allows physicians to determine whether any apparent narrowing is severe enough to merit angioplasty or stenting.

Using FFR as a diagnostic guide, interventional cardiologists can identify and stent lesions that fail to pass a blood-flow threshold, instead of stenting lesions based on angiographic characteristics. FAME shows that FFR allows for better use of stents in patients with clogged arteries, which leads to improved
outcomes. As early adopters and longtime advocates of FFR — the technique has been a part of our diagnostic toolkit. It is fair to say that the findings of the FAME study reflect what previous smaller, non-randomized studies had suggested as well as our clinical experience here at Emory.

The FFR method allows us to plan a course of treatment that is better suited to the severity of a patient’s particular condition. In general, FFR lets cardiologists fine-tune their treatment of heart-disease patients and push the whole pendulum of cardiac care more toward the conservative side — with emphasis on more intense medical therapy.

Occasionally, a patient referred for bypass surgery based on angiography alone, will undergo percutaneous intervention or medical therapy when their condition is evaluated using FFR.

FFR also correlates with a significant reduction in the number of multivessel PCIs performed in our practice. Patients who would have had stents implanted in three vessels based on angiography might end up receiving in only one or two after FFR-guided analysis. Among patients with single-vessel disease, FFR might lead us to recommend medical treatment for cases that would have otherwise received stents.

Since stents comprise the largest cost of cardiac intervention — each stent costs about $2,000 on average — FFR can significantly reduce the cost of care as it lowers the number of stents implanted and the amount of contrast dye used. But the FFR method isn’t meant to simply reduce the number of stents implanted. Stenting is a very valuable and effective procedure in cardiac care, but it is not a silver bullet.
About 30 to 40 percent of FFR procedures identify dangerous arterial narrowings that would have been missed in an angiogram, despite seriously restricting blood flow. When this happens, we will stent or even bypass areas that would have otherwise gone untreated if only angiography had been used to evaluate these patients. The cost of care increases as a result, but our patients receive treatment better tailored to their conditions.

The FAME study found that patients whose treatment was guided by FFR analysis spent less time in the hospital and experienced fewer major adverse cardiac events. All together, the benefits of FFR saved an average of $675 on each patient’s care. Some of the money saved needs to be spent on the coronary pressure guidewire, but that cost is only a fraction of the overall savings.

I used to hear physicians balk at the prospect of adopting FFR, arguing that the coronary pressure guidewire cost too much or that the procedure took too long compared to traditional treatments. The results of the FAME study appeared to have mitigated these complaints significantly.

We have the largest fellowship program in the country at Emory, so our fellows are often a very good barometer of how cardiologists nationwide are reacting to a new development in the field. Since the results of the FAME study came out, more of my experienced colleagues as well as our fellows have started to appreciate the advantages that this technique offers over angiography.

The FAME results have strengthened cardiologists’ interest in FFR by showing how the pressure wire method can improve patient care while cutting costs. It is good for the patient and for the cath lab. It is time for cardiologists to take a closer look at this physiologic technique.

Related Content

The stent struts of the Biotronik Orsiro stent.
News | Stents | December 21, 2020
December 21, 2020 – A proposed ASTM International standard will answer the need for a standardized test method that a
One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session. #AHA2020 #AHA20 #AHA

One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session.

News | Stents | November 24, 2020
November 24, 2020 — One-year results off the...
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS  study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect

Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates.

Feature | Stents | October 22, 2020 | Dave Fornell, Editor
October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durab
For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020
News | Stents | October 22, 2020
October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnolog
The FDA has cleared a new indication for the Medtronic Resolute Onyx Drug Eluting Stent, making it the first DES that only required one month of dual antiplatelet therapy (DAPT) in patients who are considered high risk for bleeding complications.

The FDA has cleared a new indication for the Medtronic Resolute Onyx Drug Eluting Stent, making it the first DES that only required one month of dual antiplatelet therapy (DAPT) in patients who are considered high risk for bleeding complications.

News | Stents | October 01, 2020
October 1, 2020 — Medtronic has received U.S.
News | Stents | July 24, 2020
July 24, 2020 — CeloNova BioSciences Inc.
Coronary and Peripheral Stent Market Expected to Double Through 2025
News | Stents | May 28, 2020
May 28, 2020 — The rising incidence of cardiovascular disease has prompted people to seek timely treatment to improve
The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration. #SCAI2020

The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration.

News | Stents | May 17, 2020
May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP)
Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the 2020 Cardiovascular Research Technologies (CRT) Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinforcing the differentiation of the Orsiro coronary drug-eluting stent (DES), which is the first DES to outperform Xience.
News | Stents | February 24, 2020
February 24, 2020 — Biotronik announced three-year data from the...
The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

Feature | Stents | February 11, 2020 | Saloni Walimbe
Cardiovascular diseases (CVDs) are among the leading causes of death across the globe.